NCT03915184View on ClinicalTrials.gov

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2034

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

zevor-cel

A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion

Trial Locations (13)

33612

Moffitt Cancer Center, Tampa

37203

TriStar CMC, Nashville

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo, Rochester

76021

UT Southwestern Medical Center, Dallas

77030

MD Anderson, Houston

Methodist Hosptial, Houston

80218

Colorado Blood Cancer Institute, Denver

84112

Huntsman Cancer Center, Salt Lake City

85054

Mayo Clinic Hospital, Phoenix

94143

UCSF, San Francisco

02215

Dana Farber Cancer Center, Boston

MSG 2C4

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY